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Abstract: The health value of honey is universally acknowledged from time immemorial. Manuka (Leptospermum scoparium) is a 
tree, indigenous to New Zealand and South East Australia, and from the myrtle family, Myrtaceae. The honey produced from its 
flowers is a uni-floral honey largely produced in New Zealand. It is becoming increasingly popular as a functional food, seen in the 
aisles of health stores as its displays superior nutritional and phytochemistry profile over other varieties of honey. Examining  
existing research databases revealed its biological properties ranging from anti-oxidant, anti-inflammatory, anti-bacterial, anti-viral, 
anti-biotic and wound healing to immune-stimulatory properties. Methylglyoxal is the unique compound in the honey responsible 
for some of its potent anti-microbial properties. Further, propolis another component of honey contains chiefly flavonoids (i.e. 
galangin, pinocembrin), phenolic acids and their esters that may also contribute to its immuno-stimulant properties. Recent findings 
of the biological roles have been discussed with emphasis on the underlying mechanisms. The hurdles associated in its  
development as a functional food and also nutraceutical with future scopes have also been mentioned. Relevant data published in 
MEDLINE, Cochrane library, and EMBASE in the past decade have been gathered to formulate this review. 
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Introduction 
The health restorative role of honey has been recognized 
since time immemorial. Even with the current use of synthetic 
anti-biotic and chemotherapeutic compounds, the use of honey 
as an anti-microbial and wound management agent has not lost 
significance. Honey is a supersaturated solution of sugars (i.e. 
glucose, fructose, sucrose and maltose), which also contains 
proteins (i.e. pollen), enzymes (i.e. glucose oxidase), amino 
acids, minerals and vitamins, and is popular as a natural clinical
treatment. A broad array of honeys are commercialized (e.g. 
alfalfa, dandelion, clover, apple blossoms, orange blossoms, 
manuka, heather, gum, neem, acacia and myriad other  
wildflowers). Manuka honey is distinguished as the most  
effective medicinal honey, yet remains largely unexplored. 
Manuka (Leptospermum scoparium) is a shrub belonging to 
the family Myrtaceae. This plant is a native of New Zealand 
and South East Australia. The name ‘manuka’ is derived from 
the Maori language, the indigenous people of New Zealand. It 
is an ornamental shrub bearing white, red or pink flowers (Fig. 
1). In Southern California, these plants are often found  
adorning gardens, parks and arboretums. The leaves are often 
brewed into a tea so it is known as the ‘New Zealand tea tree’. 
Apart from its aesthetic value, this plant has the reputation as a 
source of healthy mono-floral honey. Bees collect the flower 
nectar and process it into honey. Most of this honey is  
produced in New Zealand and then shipped to other countries. 
The unparalleled health value of this honey is ascribed to it 
phytochemical content of chiefly methylglyoxal, but also  
levels of hydrogen peroxide and D-glucono-δ-lactone which 
are derived from glucose (oxidation) and propolis. Due to its 
anti-bacterial, wound care, anti-ulcer properties, it is often 
colloquially known as a ‘healing honey’. Manuka honey is 
renowned for its prolific ameliorative effects on sore throat, 
burns, infections, gum problem, acne, indigestion; and gastro-
oesophageal reflux. This review has been compiled from  
recent published reports with an aim to disseminate the latest 
research findings on its importance and to stimulate further 
research into its use as a functional food and medical  
applications. 
As mentioned, manuka honey displays pathogen inhibition 
and wound healing actions, evident from the number of  
research articles comparing it to Portbello honey made in  
Edinburg (UK), Malaysian tualang honey, Ulmo tree honey 
from Chile, Greek and Cypriot honeys.1,2,3,4 
Manuka honey is used both internally and externally. It is 
marketed as a gel for topical applications (i.e. anti-bacterial, 
anti-fungal action, wound healing properties), capsules,  
lozenges, and drinks for oral consumption (presumed immuno-
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stimulant properties), and often re-blended with other  
functional compounds like propolis, royal jelly (inherent in the 
bee hive with raw honey possessing anti-bacterial and  
immunestimulant properties), olive leaves (Olea europaea); 
presumed hypotensive, and anti-oxidant properties due to  
iridoid glycosides (i.e. oleuropein), and ginger root (Zingiber 
officinale) extract (presumed to increase in peripheral  
circulation and anti-inflammatory properties due to pungent 
principles; i.e. gingerols and shogaols.5 
It is also used as an ingredient in anti-fungal creams for its 
clinical effect on ringworm and other fungal pathogens,  
owing to the organic acid content. It is also added to anti-itch 
creams mainly for its skin mollifying effect against eczema, 
rashes, bug bites and poisonous plant contact. A plethora of 
cosmetic products e.g. anti-wrinkle cream, facial cleanser, 
body lotion, moisturiser, soothing eye gel, lip balm, hand wash 
and soap contain this honey as a component, presumably for 
its anti-bacterial and anti-inflammatory properties. Recent 
developments in clinical use of manuka honey as a topical 
anti-microbial and wound healing agent, has been discussed to 
provide information on its clinical scope. 
 
1 Bioactive Compounds 
Manuka honey has been assessed for its nutritional and  
phytochemical composition, to predict possible clinical uses. It 
is rich in glucose oxidase that catalyses glucose to produce 
hydrogen peroxide (H2O2) which exerts anti-bacterial  
properties topically. D-glucono-δ-lactone is also produced 
which reduces the pH of the honey and in addition to the high 
sugar osmolarity exerts natural anti-bacterial properties and 
renders the honey shelf-stable. The low water activity of honey
in general (0.6–0.75) also renders it uninhabitable for most 
micro-organisms.6 Further, propolis is another nutritionally 
important component in honey, as it has been reported that  
p-coumaric acid in it up-regulates both detoxification and anti-
microbial peptide in vivo in bees (Apis mellifera)7. The level of 
propolis in the honey varies due to the processing to remove 
particular matter such as pollen. Propolis also contains 
galangin, pinocembrin, and phenolic acids which have been 
shown to display anti-inflammatory effects in asthma, cerebral 
ischemic protective effects and anti-inflammatory/anti-oxidant 
properties.8,9 
Methylglyoxal, the aldehyde form of pyruvic acid is the 
chief anti-bacterial compound in this honey. Unique manuka 
factor (UMF) is quality marker to identify and market  
unadulterated manuka honey. Apart from the methylglyoxal 
content, methyl syringate, ortho-methoxyacetophenone and 3-
phenyllactic acid are other abundant components.10 
Methyl syringate and its novel glycoside; methyl syringate 
4-O-β-D-gentiobiose (also known as leptosin) are anti-
oxidants, commonly found at concentrations between 0.2 to 
1.2 μmol/g honey, and its positively associated with UMF, 
which is expressed as phenol equivalents of its inherent anti-
bacterial activity11. High concentrations of 4-hydroxybenzoic 
acid (4BHA), dehydrovomifoliol and benzoic acid was reported
in the honey. 4BHA has been shown to inhibit pancreatic  
lipases, which are important for the digestion of dietary fats in 
pigs, whereas benzoic acid and its derivatives display anti-
fungal activity to various species, e.g. Fusarium oxysporum, 
which is pathogenic to humans i.e. fungal keratitis.12,13 
Kojic acid (KA), unedone, 5-methyl-3-furancarboxylic  
acid, 3-hydroxy-1-(2-methoxyphenyl)penta-1,4-dione, and 
lumichrome were identified in the honey for the first time. 
Kojic acid is known to enhance the properties of known  
anti-fungal agents (i.e. amphotericin B and strobilurin).15  
Dihydroxyacetone is the precursor of methylglyoxal. It was 
quantified in fresh manuka honey to be between 600 to 2700 
mg/kg and 130 to 1600 mg/kg in commercial manuka honey. 
Methylglyoxal content was measured from 50 to 250 mg/kg  
in fresh and 70 to 700 mg/kg in commercial manuka honey 
samples.16 
 
2 Therapeutic Roles 
2.1 Antioxidant and Anti-inflammatory Activities:  
Oxidative stress (e.g. cell membrane or DNA damage), is 
caused by the formation of reactive oxygen species (ROS) 
such as O–, which are natural by-products of metabolism. The 
body has a number of defence systems against ROS such as 
anti-oxidants i.e. endogenous enzymes such as superoxide 
dismutase, catalase, glutathione peroxidases and exogenous 
dietary anti-oxidants such as ascorbic acid tocopherols,  
glutathione. Oxidative stress reduction by manuka honey is 
well-evidenced. The radical scavenging activity for superoxide 
ions is attributed to methyl syringate.17 Further, the flavonoids 
 
Figure 1.  Leptospermum scoparium plants abloom in summer, Orange County, California. 
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galangin, pinocembrin, and phenolic acids (i.e. gallic acid) 
found in the propolis fraction of honey and have known anti-
oxidant activities5. The anti-inflammation potency of manuka 
honey was investigated and dose-dependent reduction of in 
vitro human neutrophil superoxide production was reported. 
Further, in a C57BL/6 J mouse model, the topical application 
of the honey suppressed ear oedema induced by arachidonic 
acid.18 Moreover, internal application possibility of manuka 
honey against H. pylori-induced gastric inflammation was 
explored. It demonstrated appreciable activity and potentiated 
the anti-inflammation effect of isothiocyanate-rich broccoli 
sprouts19, possibly via reduced cytokine (i.e. macrophage  
induced IL-8 release) induced ROS formation/ or activity in 
the stomach mucosal tissue. Furthermore, the anti-
inflammatory activity of raw and α-cyclodextrin-encapsulated 
manuka honey was shown to inhibit neutrophil TNF-α  
secretion, and in-turn reduce inflammation. The anti-
inflammation mechanisms require investigation of concerned 
gene regulation20. In a trial comparing the anti-oxidant activity 
of manuka honey with acacia honey from Germany and wild 
carrot honey, the former was deemed superior in its phenolic 
content (899.09 mg gallic acid/kg).21 It was observed that  
manuka honey has significantly higher levels of the  
polyphenols and antioxidant activity than portbello honey (a 
honey made in Edinburg, UK)1 
Even though trials have been conducted on total anti-
oxidant content of the honey, and respective clinical outcomes, 
further research needs to be conducted. Determination of the 
specific therapeutic role of the anti-oxidants and co-factors in 
manuka honey may reveal synergistic activities. The reduction 
of inflammation (i.e. cytokine hormones TNF-α, IL-6),  
appears functionally important to support the immune system 
to defend against microbial infection.22 
 
2.2 Anti-bacterial, Anti-biotic, and Anti-viral Effects: 
The broad spectrum anti-bacterial activity of manuka honey 
has been validated through numerous clinical trials and in vivo 
bacterial challeges ranging from oral infections, dermatitis  
and skin irritations, intestinal inflammation to nosocomical 
pathogens. 
The capacity of manuka honey with UMF 15 was  
investigated in reducing dental plaque and clinical levels of 
gingivitis. Gingivitis is a non-destructive dental disease caused 
by bacterial plaque and subsequent gum inflammation. The 
randomized study conducted on 30 subjects for a 21-day trial 
period showed that there was a significant reduction in the 
mean plaque scores and the percentage of bleeding sites in the 
group administered with chewy or liquid manuka honey. This 
honey may be developed for non-cariogenic confectionery to 
avert gingivitis and periodontal diseases.23 In a further study, 
the effect of manuka honey, chlorhexidine gluconate mouth-
wash (chemical anti-septic effective against both Gram  
positive and negative bacteria) and xylitol chewing gum were  
compared on dental plaque formation. Sixty healthy subjects 
received either prophylaxis prior to the study’s commencement
and then were randomly divided into three groups. After the 
experimental period of 72 h, the plaque level was measured 
using the Quigley and Hein plaque index. The statistical tests 
revealed that the plaque inhibition by manuka honey was  
similar to that of chlorhexidine mouthwash, which was  
significantly better than xylitol chewing gum.24 Moreover, the 
effect of manuka honey on potentially pathogenic oral bacteria 
was investigated using the macro dilution broth technique. 
Manuka showed a total inhibition of multi-species biofilm at 
the concentration of 200–500 μg/mL. This honey might be 
able to reduce oral pathogens within dental plaque,25 possibly 
due to H2O2, as it has been shown previously to display anti-
microbial effect against dental plaque at 0.5% concentration 
with chlorhexidine.26 
It was reported that dressings impregnated with irradiated 
manuka honey suppressed staphylococcal infections in  
hidradenitis suppurativa (a chronic skin disease affecting areas 
with sebaceous glands), by reducing the time of healing.27 
Moreover, the effect of manuka honey in inhibition of  
Staphylococcus aureus and the mechanism of action were  
investigated. The bactericidal effects were established by 
marked structural changes in the honey-treated cells as  
observed with TEM. The cells were inhibited in completion of 
the cell cycle (increased number of whole cells with completed 
septa) as the honey interfered with cell division machinery.28 
Rhinosinusitis is the inflammation of the mucous membrane 
that lines the paranasal sinuses. Pseudomonas aeruginosa and 
Staphylococcus aureus are known to be associated with this 
pathological condition. The in vitro effect of methylglyoxal 
against both pathogens was determined. The compound  
proved effective against both planktonic form and biofilm of 
methicillin-resistant S. aureus and P. aeruginosa.29 The effect 
of manuka honey on P. aeruginosa was investigated and an 
inhibitory efficacy was confirmed. The honey affected the key 
micro-colony forming genes (i.e. algD and oprF) and causes 
cell lysis. 
The anti-microbial potency (agar incorporation method) and 
total phenol content (free radical scavenging activity) of  
several honeys were determined. Manuka honey showed 
strong efficacy against S. aureus. This honey had the highest 
content of polyphenols with 899 mg gallic acid/kg.31 The non-
peroxide anti-bacterial effects of manuka honey on the  
proteome of S. aureus was determined. The treatment resulted 
in a significant decrease in the bacterial cell growth rate as 
well as modulation in gene expression of number of  
proteins. The honey induced down-regulation of two proteins; 
dihydrolipoamide dehydrogenase (DLD) and elongation factor 
Tu (EF-Tu). DLD is a mitochondrial enzyme involved in  
glycine cleavage system1 and EF-Tu is part of a mechanism 
for protein synthesis (i.e. ribosomal protein translation). On 
the other hand, up-regulation of cold shock protein C (CspC) 
was observed32. CspC is responsible for survival of cells below 
optimal growth temperatures, a possible signalling pathway for 
apoptosis in S. aureus. Moreover, the in vitro effect of manuka 
honey on Streptococcus pyogenes M28 was investigated.  
Bactericidal effects were found in both planktonic cultures and 
biofilms, although higher concentrations of honey were needed 
to inhibit the biofilms. The honey penetrated into a day-old 
biofilm and interfered with adherence, leading to cell death. 
The inhibition of binding with the human tissue protein  
fibronectin was observed and confirmed by a reduction in the 
expression of genes Sof and SfbI. The promising role of honey 
in eliminating S. pyogenes from wound site and rendering skin 
graft free from sepsis became evident33. 
The genus Campylobacter causes campylobacteriosis, a  
disease with symptoms including diarrhoea, cramping,  
abdominal pain, and fever in the infected patients. The anti-
microbial effect of manuka honey against a clinical isolate of 
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Campylobacter spp. was reported. The minimum inhibitory 
concentration (MIC) of the honey against the strains was 
found to be around 1% (v/v) honey. The low MIC values  
suggest that honey may still inhibit the growth of the pathogen 
after dilution by fluid in the gut.34 In fact, honey requires  
dilution to raise the pH and thus activate glucose peroxidise, 
the enzyme that cleaves glucose to yield H2O2 and D-glucono-δ-lactone. 
It was observed that manuka honey is significantly more  
effective than artificial honey (a mixture of sugars rather than 
natural honey) against many gut pathogens including  
Enterobacter spp. The antimicrobial action as determined by 
micro-dilution method established that besides osmolarity, the 
anti-microbial compounds (i.e. H2O2, methylglyoxal) are  
responsible for the observed effect. The honey may be used to 
inhibit multi-antibiotic resistant microorganisms such as  
Salmonella typhimurium DT104 and extended-spectrum β-
lactamase (ESBL)-producing organisms.35 
Stenotrophomonas maltophilia is often associated with  
hospital-induced infection. The bacteria colonize breathing 
tubes and urinary catheters. Manuka honey is effective against 
this pathogen even at very low MIC. Also, it inhibited  
Acinetobacter baumannii, a serious pathogen with resistance 
to most antibiotics.2 Further, manuka honey showed inhibition 
against several wound bacteria e.g. Bacillus subtilis,  
Escherichia coli, Staphylococcus aureus and Pseudomonas 
aeruginosa. Though not the sole active component, hydrogen 
peroxide was credited with a partial antibacterial activity.36,37 
For effective wound management, the anti-biofilm effect of  
manuka honey was investigated against Proteus mirabilis and 
Enterobacter cloacae wound isolates. The micro-titer plate 
assay revealed that the honey at a sub-inhibitory concentration 
of 10% (w/v) significantly reduced the biofilm development of 
both isolates. Similarly, at a concentration of 50% (w/v), it 
caused significant partial detachment of P. mirabilis biofilm 
after 24 h. Treatment of both biofilms with the honey resulted 
in a significant decrease in colony-forming units per well, with 
values ranging from 0.35–1.16 and 1.2–7.5 log units,  
respectively. The anti-biofilm property of the honey was  
attributed to methylglyoxal.38 
Currently, anti-biotic use poses a well established  
impediment, due to the emergence of resistant bacteria. On the 
other hand, due to multi-phytochemical composition and the 
array of differing anti-microbial mechanisms, manuka honey 
seems well presented to inhibit even antibiotic-resistant  
‘superbugs’. It was observed that manuka honey and oxacillin 
interacted synergistically to inhibit methicillin-resistant  
Staphylococcus aureus (MRSA). The honey reversed oxacillin 
resistance in MRSA and down-regulated mecR1 (a gene that 
regulates the expression of methicillin resistance).39 Moreover, 
the anti-microbial synergistic efficacy of manuka against 
MRSA and P. aeruginosa was evaluated using disc diffusion, 
broth dilution, E strip, chequerboard titration and growth 
curves. Five novel anti-biotics (piperacillin/tazobactam,  
rifampicin, tetracycline, imipenem and mupircoin) and manuka
honey combinations were observed to improve anti-bacterial 
effectiveness in vitro.40 The effect of ‘Medihoney®’ in  
combination with the widely used anti-biotic rifampicin were 
investigated. Using checkerboard micro-dilution assays, time-
kill curve experiments and agar diffusion assays, a synergism 
between the two agents was observed against MRSA. The 
inhibitory principle was suspected to be other than the major 
component methylglyoxal41 as catalases protect biofilm against 
lethal doses of H2O242. 
The in vitro anti-viral effect of manuka honey on Varicella 
zoster (a herpes virus that cause chickenpox and the shingles) 
virus was determined examined. Different concentrations of 
manuka honey were added to the tissue culture medium of the 
virus-infected human malignant melanoma cells. This honey 
showed anti-viral activity against the virus and might be an 
excellent remedy for zoster rash in developing countries where 
anti-viral drugs are either expensive or not easily available.43 
The anti-microbial and anti-viral effectiveness of manuka  
honey has been shown across a range of micro-organisms and 
viruses mainly due to its broad spectrum of phytochemicals 
present and their varying degree of mechanisms. This may aid 
in the anti-inflammatory effects on ulcers and wounds. 
 
2.3 Anti-ulcer and Wound Healing: Recurrent wound  
infections complicate the healing process, and may exacerbate 
inflammation of the wound site. However, cytokines and other 
mediators of inflammation may cause ‘out-of-control  
inflammatory response’ and hamper wound management.44 
Manuka honey has been proven to be an effective agent in 
healing diabetic wounds, venous ulcers, burns, acne, eczema, 
psoriasis. The effects of manuka honey dressing on the pH and 
size on non-healing chronic superficial ulcers were studied. 
Manuka honey (Apinate® brand name) was applied to wounds 
for 2 week duration. After the specified time, a significant 
decrease in wound pH (pH 8 to 7.6) was observed, with every 
0.1 pH unit decrease was associated with a 8.1% reduction in 
wound size. Thus, reduced pH promotes wound healing via 
increased fibroblast activity, inhibition of protease activity and 
oxygen release45. Moreover, in a randomized control trial, 
manuka honey improved wound healing in a patient with 
sloughy venous leg ulcers.46 The case of a 55-year-old woman 
with necrotic lesions of the abdominal integuments and the 
lumbar area following traumatic colonic rupture was reported. 
When treated with manuka honey wound dressings combined 
with the GENADYNE A4 negative pressure wound therapy 
system, it enabled skin auto-grafting on the wound site and 
facilitate the wound healing.47 Further, a case study was  
conducted on a 102-year-old patient with a painful infected 
venous ulcer complicated by arterial disease. The combination 
of the superabsorbent KerraMax® (Crawford Healthcare) with 
the anti-bacterial properties of manuka honey Algivon®  
(Advancis Medical) created the ideal dressing for the treatment 
of the mixed aetiology ulcer. It protected the wound site 
providing an anti-bacterial environment, and inhibiting  
bacterial growth48. In an animal study, the effect of manuka 
honey gel in ameliorating the wound in the distal limb of a 
horse was investigated. The treatment using honey and its gel 
reduced wound retraction and overall healing time compared 
to untreated control wounds.49 The case study of leg injury 
was reported where manuka honey could stimulate production 
of collagen and thus repaired the connective tissue (i.e. skin). 
The honey led to complete healing in two weeks. Its efficacy 
in managing wound healing raises the possibility of its usage 
in curing Ehlers-Danlos syndrome, a rare inherited disorder 
characterized by loose joints, fragile skin and blood vessels.50 
Moreover, the efficacy of manuka honey in the treatment of 
chronic or recurrent pilonidal sinus disease, an abscess near 
the natal cleft was investigated. Out of the 17 patients who 
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received manuka honey dressing therapy after surgery, 15 
achieved complete healing, in a mean time of 65 days.51 The 
efficacy of several types of honey, including manuka was  
investigated in an in vitro model of HaCaT (immortal human 
keratinocyte cell line) re-epithelialization where the epithethial 
cells re-generate over wound bed. A component of the honey 
activated cyclin-dependent kinase 2, focal adhesion kinase and 
rasGAP SH3 binding protein 1, a protein related to apoptosis 
of damaged and adhesion of new keratinocytes. The wound 
repair was deduced to be due the activation of keratinocyte re-
epithelialization. Manuka honey induced few significant 
changes compared to other honeys in the expression of  
epithelial-mesenchymal transition-regulatory genes.52 This 
evaluation demonstrated that manuka honey causes a  
significantly greater reduction of the wound surface area  
compared to the standard treatment of leg ulcers53, possibly via 
methylglyoxal-derived AGE products (i.e. argpyrimidine) 
which induced NF-κB activation and subsequent apoptosis in 
lens epithethial cells.54 
Moreover, the effectiveness of manuka honey-impregnated 
dressings on the healing of neuropathic diabetic foot ulcers 
was investigated. A total of 63 patients with type 2 diabetes 
were randomized to receive either conventional or manuka-
soaked dressing. The patients were followed up on a weekly 
basis for 16 weeks to review the progress of the ulceration. 
Mean healing time was approximately 31 days for manuka 
dressing compared to 43 days in conventional dressing. 
Though the percentage of ulcers healed did not vary  
significantly between the two groups (97% for manuka  
dressing and 90% for conventional dressings), the reduction of 
healing time and rapid disinfection of ulcers by manuka honey 
treated group were apparent.55 
The effect of culture media supplemented with a lyophilized 
preparation rich in growth factors and manuka honey in 
wound-healing was determined. Human fibroblasts,  
macrophages, and endothelial cells when subjected to the 
blend, demonstrated increases in cellular activity in the  
presence of PRGF, with further increases in activity seen in 
the presence of PRGF + MH. The fibroblasts proved to be the 
most positively responsive cells, as they experienced enhanced 
proliferation, collagen matrix production, and migration into 
an in vitro wound healing model with the supplemented media. 
Enhancement of dermal regeneration potential was evident.56 
The effect of wound healing may be a culmination of both the 
anti-inflammatory effect, anti-microbial as well as immuno-
stimulatory effect of manuka honey. Immuno-stimulation, in 
particularly the elevated level of cytokine hormones is merited 
as one mechanism for wound repair. 
 
2.4 Immune-stimulatory: The immuno-stimulatory effect 
of manuka honey has often been accredited to a number of its 
phytochemicals; gallic acid, and flavonoids; galangin,  
pinocembrin. It has been reported that manuka honey increases 
IL-1β, IL-6, and TNF-α production from Mono Mac6 cells or 
human monocytes.57 On the contrary, cytokine elevation is a 
by-product of inflammation and cytokines would presumably 
decrease with consumption of manuka honey as phytochemi-
cals such as gallic acid inhibit inflammation induced NF-κB, 
interleukin-1β, and TNF-α expression.58 Further, both pro-
inflammatory and anti-inflammatory effects of manuka honey 
was observed. The contradictory results of stimulation as well 
as inhibition of TNF-α was attributed to the formation of AGE 
products of methylglyoxal which is correlated to systemic 
TNF-α levels59,60. Further, a small molecular weight compound 
from manuka honey was isolated by filtration followed by 
reverse-phase solid-phase extraction. The bioactive component 
stimulated production of TNF-α via TLR4, suggesting it is 
related to the innate immune system response. Blocking TLR4 
significantly inhibited honey-stimulated cytokine production.61 
Also, the ability of manuka honey was assessed in eliciting the 
release of TNF-α from monocytic cell lines THP-1 and U937 
which stimulated TNF-α release from THP-1. Further in vivo, 
rather than in vitro cell line research needs to be conducted to 
confirm the effect of manuka honey on cytokine hormone  
release from macrophages as a true reflection of immune  
response. 
 
2.5 Anti-tumour Potential: The anti-proliferative activity 
of manuka honey was investigated on murine melanoma 
(B16.F1), colorectal carcinoma (CT26) and human breast  
cancer (MCF-7) cells in vitro. The results displayed a time- 
and dose-dependent effect, with maximal efficacy at 0.6% 
(w/v). Furthermore, the activation of a caspase 9-dependent 
apoptotic pathway, led to the induction of caspase 3 which 
encoded for reduced Bcl-2 expression, DNA fragmentation 
and final apoptosis.45 An in vivo syngeneic mouse melanoma 
model was used to assess the potential effect of intravenously-
administered manuka honey alone and in combination with 
paclitaxel. The treatment with honey alone resulted in a 33% 
inhibition of the tumour growth. However, a better control of 
tumour growth was observed in animals treated with paclitaxel 
combined with manuka honey (61% inhibition).62 Further, 
gallic acid, an important phenolic acid present in manuka  
honey has been shown in an alcoholic extract of Potentilla 
fulgens which reduced Ehrlich ascites tumour in mice and 
MCF-7 cancer cells via induction of apoptosis by the  
inhibition of the protein survivin and glutathione lowering 
effect.63 
It must be stated that cell cultures do not represent a whole 
living organism, as the effects of digestion, enterocyte and 
hepatic conjugation of phytochemicals may modify their 
chemical structure and therefore their effectiveness. Further 
human trials are needed to confirm the effectiveness of manuka
honey phytochemicals both solo and in synergy. 
 
3 Mechanisms of Action 
The mechanisms of therapeutic actions of manuka honey 
have been adequately deduced. Many factors have been  
attributed to its clinical implications, as the honey contains a 
multitude of phytochemicals. Recalcitrant wounds generally 
have an alkaline milieu. The bacterial proteases are active in 
alkaline condition and increase the risk of infection. The acidic 
pH of manuka honey lowers the alkalinity, thus inactivates the 
proteases and helps in healing. Further, the honey increases 
fibroblast activity (stimulated by cytokines) and oxygen  
release (aerobic condition hampers pathogenic growth),  
augmenting the remedial process.45 The acidity of manuka 
honey may be attributed to the presence of D-glucono-δ-
lactone, phenolic and organic acids. D-glucono-δ-lactone is 
used in food technology as an acidifier with the E number 
E575, and is partially hydrolyzed in water to its acidic form; 
gluconic acid. It is suggested that the ‘low pH effect’ of  
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Biological roles In vitro In vivo Clinical trials References
Antioxidant and anti-
inflammatory 
Radical scavenging activity; 
 
Reduction of human neutrophil superoxide 
production; 
 
Enhancement of the antiinflammatory effect 
of broccoli 




Total inhibition of multi-species biofilm; 
 
Suppression of the staphylococcal infections 
in hidradenitis suppurativa; 
 
Interference with cell division machinery of 
Staphylococcus aureus; 
 
Inhibition of planktonic form and biofilm of 
methicillin-resistant Staphylococcus aureus 
and P. aeruginosa; 
 
Decrease in the Staphylococcus aureus cell 
growth rate as well as modulation in gene 
expression; 
 
Inhibition of Streptococcus pyogenes, 
Campylobacter spp24, multi-antibiotic 
resistant microorganisms such as 
Salmonella typhimurium DT104, 
Stenotrophomonas maltophilia and 
Acinetobacter baumannii; 
 
Reduction in the biofilm development of 
Proteus mirabilis and Enterobacter cloacae;
 
Synergy with antibiotic against MRSA and 
P. aeruginosa 
 Reduction in the mean plaque 
scores and the percentage of 
bleeding sites 
23, 24, 25, 
27, 28, 29, 
30, 31, 32, 
33, 34, 35, 
36, 38, 39, 
40, 41 
Antiviral Inhibition of varicella zoster virus 43
Antiulcer and wound-
healing 
Wound repair due to the activation of 
keratinocyte re-epithelialization; 
 
Enhancement of dermal regeneration with 
combination to growth factors 
Reduction of 
wound retraction 
and overall healing 
time in horse 
Decrease in the pH led to 
reduction in wound size; 
 
Improvement of wound  
healing in patients with 
sloughy venous leg ulcers; 
 
Enable skin auto-grafting on 
the wound site; 
 
Stimulation of production of 
collagen; 
 
Helpful in the treatment of 
chronic or recurrent pilonidal 
sinus disease; 
 
Reduction of healing time 
and rapid disinfection of 
ulcers neuropathic diabetic 
foot ulcers 
45, 46, 47, 
48, 49, 50, 
51, 52, 53 
Immunestimulatory Increase in IL-1β, IL-6, and TNF-α
production from Mono Mac6 cells, 
monocytic cell lines THP-1 and U937 
51, 57, 61
Antitumor Dose-dependent anti-proliferative effect on 
murine melanoma (B16.F1) and colorectal 
carcinoma (CT26) as well as human breast 
cancer (MCF-7) cells i 
33% inhibition of 




manuka honey would be due to the gluconic acid released 
from D-glucono-δ-lactone when it metabolises with aqueous 
wound exude. When applied topically, honey dries the mucus 
of skin injury site and renders the wound inhospitable for  
bacterial proliferation. The viscous honey when slathered on 
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dressing, creates an osmotic pull, that helps the absorption  
of excess wound exudates, with hydrogen peroxide, methyl-
glyoxal display anti-bacterial effects to inhibit the growth of 
pathogenic bacteria. Methyglyoxal is toxic towards pathogens 
even at very low concentrations interrupting cell division,  
arresting growth, and specifically causing the degradation of 
bacterial DNA.64 
 
4 Issues Encountered 
Though the benefits of manuka honey have been widely 
documented, there are instances of adverse effects that  
warrants thorough safety analysis before mass prescription is 
undertaken. Methylglyoxal in this honey is responsible for 
imparting the strong anti-bacterial activity. However, it also 
serves as precursor of advanced glycation end products (AGEs).
Methylglyoxal, along with its derivatives, impair diabetic 
wound healing by interferring with the target molecules (i.e. 
forming adducts on proteins and DNAs, the anomalous cross-
linking leading to reduced collagen elasticity, enhancing  
neutrophil activity resulting in inflammation).65 Also, this  
glycating agent is associated with increased atherogenicity. It 
has been observed to modulate low-density lipoprotein into 
small, dense particles further increasing the cardiovascular risk 
in diabetics.66 It binds to proteins that contribute to the  
morbidity of aging and diabetes mellitus, such as renal  
diseases.67 A prospective, controlled study on chinchilla was 
conducted to determine the ototoxic effects of manuka honey. 
After 2 weeks of administration into the ears, the chochleae 
were removed for analysis. At 50% concentration, manuka 
honey exerted bactericidal properties against biofilms of  
Pseudomonas aeruginosa and Staphylococcus aureus.  
However, this concentration led to facial paralysis,  
vestibulotoxicity and hearing loss.68 Often, kanuka honey is 
traded as manuka honey, which lacks the nutritive quality of 
the latter. 
 
5 Future Directions 
Escalated research is required to further analyze the  
phytochemical spectrum and the pharmaceutical refinement of 
active constituents in manuka honey. Further verification is 
required to determine whether geographical region has any 
impact on the composition of honey. At present, the honey 
production remains confined to New Zealand though it may be 
grown in other parts of the world. Currently, manuka plants 
grow in Southern California and may prove suitable for  
harvesting quality honey. The possibility of fortifying foods 
with this honey and therapeutic applications should be  
explored for possible development of nutraceuticals. For  
example, the addition of methylgyloxal has been shown in 
chicken breast patties to reduce the food pathogen Salmonella 
typhimurium and S. enteritidis, extending manuka honey's 
application to food technology and public health.69 Further-
more, the honey has been suggested to possess anti-fungal 
property but there is no empirical data to validate the efficacy 
and thus may be the next crucial step to explore these claims. 
The presence of kojic, benzoic and gallic acids (GA) in  
manuka honey suggest that they may be responsible for the 
anecdotal anti-fungal properties although further research is 
needed. Investigating its anti-cancer potential with other  
immuno-modulating and anti-oxidant containing herbal  
extracts such as Cat’s claw (Uncaria tomentosa), or Lingzi 
(Ganoderma lucidum) may also be a significance contribution 
as a combined multi-facet complementary therapy. 
 
6 Conclusions 
Antibiotic resistance of bacteria is on the rise, thus the  
discovery of alternative therapeutic agents are justified. The 
recognition of biological activities of manuka honey is soaring 
and more research impetus may reveal increased clinical uses. 
More randomized controlled trials are required to determine 
the efficacy and safety of manuka honey. Further investigation 
is warranted to identify the active components and  
mechanisms responsible for these activities. Given adequate 
research attention, these phytochemicals can be used more 
extensively in complementary medicine either as isolated 
compounds or as whole honey extracts. A range of honey-
based products may also be developed to enhance the existing 
anti-biotic and anti-septic creams, using manuka honey in 
more readily available forms. 
 
Open Access This article is distributed under the terms of the  
Creative Commons Attribution License which permits any use,  
distribution, and reproduction in any medium, provided the original 
author(s) and source are credited. 
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